Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan paediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs.
Odevixibat is a potent and selective inhibitor of the ileal bile acid transporter (IBAT), sometimes also referred to as the apical sodium dependent bile acid transporter (ASBT), that has minimal systemic exposure at therapeutic doses and acts locally in the gut.
Odevixibat has the potential to become the first approved pharmacologic treatment for patients with PFIC. The Company intends to complete regulatory filings in the EU and in the U.S. no later than early 2021, in anticipation of potential regulatory approval, issuance of a rare pediatric disease priority review voucher and launch in the second half of 2021, if approved. The Company also plans to initiate a pivotal Phase 3 trial of odevixibat in Alagille syndrome by the end of 2020, and to continue enrolling patients in the BOLD pivotal Phase 3 trial of odevixibat in biliary atresia. Albireo continues to progress its pipeline and expects to complete IND-enabling studies for a new preclinical candidate this year.
The U.S. Food and Drug Administration (FDA) has granted to the odevixibat PFIC program or elements of it fast track, rare paediatric disease and orphan drug designations. The European Medicines Agency (EMA) has granted odevixibat orphan designation, as well as access to the PRIority MEdicines (PRIME) scheme for the treatment of PFIC. Its Paediatric Committee has agreed to Albireo's odevixibat Pediatric Investigation Plan for PFIC. Both FDA and EMA also have granted orphan drug designation to odevixibat for the treatment of Alagille syndrome and primary biliary cholangitis. Albireo will commercialise Odevixibat in the US, Europe & Canada and will partner in remaining regions.
Job Title: National Accounts Director
Reports To: Senior Director, National Accounts
Location: Boston, MA
The National Accounts Director position reports to the Senior Director, National Accounts and is responsible for developing and leveraging relationships with National 3rd Party Payers, to gain and maintain access for Albireo products. This strategically important role for the organization is responsible for the implementation of short- and long-term business plans that will optimize appropriate coverage, payment of and patient access to Albireo products. This individual will assess sales implications of short- and long-term actions with each payer customer and take action to move payer decisions in a direction that continue to open patient access to care. These actions will be a result of building strong relationships with payer Medical and Pharmacy Directors (clinical and administrative), Case Managers, and other Pharmacy and Medical benefit managers. Efforts will include working with national headquarters of managed care organizations and executing pull-through and contracting strategies to local offices of the national organizations, as well as initiatives with other large and local managed care organizations. The National Account Director is expected to work with minimal supervision and strategic independent thought. This individual will work closely with Marketing, Account Management, Finance, Government and Sales Leadership, to ensure consistent exchange of important payer information and messages that should be communicated. This role will provide periodic market updates to Sales Management that link important provider, payer and health care reform trends and issues as well as documents initiatives and their outcomes. The position is remotely based and will cover the Western region of the U.S.
Key Duties and Responsibilities:
Work with the various Albireo Patient Services Hub and case managers to assure accurate coverage determinations are rendered and resolve customer issues
Field-based. Requires up to 25-30% travel
Equal Opportunity Employer
All applicants should be legally entitled to work for any employer in the U.S.
Note to employment agencies: Please do not forward any agency resumes.